Drug intelligence / Profile preview

Tiaogan Lipi

Development stage: Unknown
Lead developer: Beijing Hospital of Traditional Chinese Medicine
Administration: Oral

Overview

Tiaogan Lipi is a Traditional Chinese Medicine (TCM) herbal formulation developed by the Beijing Hospital of Traditional Chinese Medicine. It is primarily used as an adjuvant therapy for patients with primary liver cancer (hepatocellular carcinoma), particularly those undergoing transcatheter arterial chemoembolization (TACE). The formula is based on the TCM principle of "regulating the liver and strengthening the spleen" (Tiaogan Lipi), which aims to address the underlying systemic imbalances associated with liver disease. Clinical research, such as trial ChiCTR-IOR-16008036, evaluates its efficacy in preventing recurrence and improving the quality of life and liver function in post-TACE patients.

Other names: Tiaogan Lipi granuleTiaogan Lipi approach

Beyond the preview

Go deeper on Tiaogan Lipi.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tiaogan Lipi.

Explore the full profile